查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1627883

全球免疫檢測市場：預測（2025-2030）

Global Immunoassay Market - Forecasts from 2025 to 2030
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 135 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

免疫檢測市場預計將以 6.46% 的複合年成長率成長，從 2025 年的 355.71 億美元增至 2030 年的 486.44 億美元。

免疫檢測是一種利用抗原抗體親和性來識別和定量生物檢體中目標分子的生物分析方法。在實驗室中進行的快速且準確的測試，用於識別特定物質。

癌症、糖尿病、心血管疾病和自體免疫疾病等慢性疾病的增加對免疫檢測市場的成長做出了重大貢獻，因為它對早期診斷和監測以改善疾病管理具有重要意義。

根據國際糖尿病聯盟（IDF）估計，到 2030 年，患有糖尿病的成年人（20 至 79 歲）人數預計將增加到 6.43 億。 2021年，人​​口約為5.37億，但預計到2045年將增加至7.83億。統計數據預測，對早期診斷和明確檢測設備的需求將會增加，因此未來對免疫檢測的需求也會增加。

此外，感染疾病的流行和發病率的增加正在推動市場的成長。根據世界衛生組織（WHO）2024年5月發布的資料，醫療保健相關感染和抗菌藥物抗藥性的負擔巨大，每年有超過24%的膿毒症患者和52.3%的加護病房患者死亡。藥感染疾病患者的死亡率高出兩到三倍。

此外，以如何識別各種感染疾病的徵兆並採取預防措施為重點的公共衛生教育宣傳活動有助於提高公眾意識並控制其他疾病。患者意識的提高預計將導致對免疫檢測的高需求。

免疫檢測市場成長驅動力

  • 慢性病盛行率增加

患有癌症、糖尿病等慢性疾病的患者數量正在增加。這增加了對免疫檢測裝置檢測患者特定生物標記的需求。國際癌症研究機構（IARC）發布了2022年全球各地區新發癌症病例絕對數和癌症發生率統計數據。亞洲癌症病例數最多，佔總數的49.2%，有982.6萬例。其次是歐洲，佔 22.4%，即 4,471,000 人；其次是北美，佔 13.4%，即 2,673,000 人。免疫檢測對於收集慢性病生物標記以改善患者治療管理至關重要。此類生物標記透過根據患者的健康狀況設計治療計劃、監測治療反應並在診斷疾病後修改治療策略來支持個人化醫療保健。

免疫檢測市場的地理前景：

  • 預計亞太地區免疫檢測市場將顯著成長。

由於對穩健的醫療基礎設施的投資增加以及慢性病盛行率的增加，預計亞太地區將在免疫檢測市場中佔據重要地位。日本免疫檢測市場呈現穩定成長。其成長的特徵是人口老化、慢性病盛行率高以及對早期診斷工具的需求不斷增加。日本擁有世界一流的醫療基礎設施和高品質的醫療服務，大多數醫院、診所和研究機構都使用免疫檢測技術。老年人口占日本總人口的比例逐漸上升，2020年將達到28.56%，2021年將達到28.86%，2022年將達29.00%。 RUO免疫檢測是診斷和治療老年人慢性病的寶貴研究工具。

Sysmex Corporation（總部：日本神戶）和 Fujirebio Holdings, Inc.（總部：日本東京）已同意於 2023 年 10 月建立業務合作夥伴關係。該協議將加強我們在免疫檢測領域的研發、生產、臨床開發、銷售和行銷等各領域的合作關係。此外，我們也同意簽訂免疫檢測專用試劑和原料的供應協議。透過利用各自的免疫檢測專業知識和能力，兩家公司將推動全球成長，並為該診斷領域的發展做出重大貢獻。

隨著超靈敏技術的進步，需求不斷增加，特別是在神經感染疾病和腫瘤學檢測領域。靈敏度的提高使得能夠在所有檢測和診斷領域發現較低水平的新標記。因此，新的創新產品的開發預計將在預測期內推動免疫檢測市場的發展。

為什麼要購買這份報告？

  • 富有洞察力的分析：獲得涵蓋關鍵和新興地區的深入市場洞察，重點關注客戶細分、政府政策和社會經濟因素、消費者偏好、行業和其他子區隔。
  • 競爭格局：了解世界主要企業所採用的策略策略，並了解正確策略的市場滲透潛力。
  • 市場趨勢和促進因素：探索動態因素和關鍵市場趨勢以及它們將如何影響未來的市場發展。
  • 可行的建議：利用洞察力做出策略決策，在動態環境中發現新的業務流和收益。
  • 受眾廣泛：對於新興企業、研究機構、顧問、中小企業和大型企業有用且具有成本效益。

它有什麼用？

產業和市場考量、機會評估、產品需求預測、打入市場策略、地理擴張、資本投資決策、法律規範與影響、新產品開發、競爭影響

調查範圍

  • 2022年至2030年歷史資料與預測
  • 成長機會、挑戰、供應鏈前景、法規結構、顧客行為、趨勢分析
  • 競爭對手的市場狀況、策略與市場佔有率分析
  • 包括國家在內的細分市場和地區的收益成長和預測評估
  • 公司簡介（策略、產品、財務資訊、主要發展等）

免疫檢測市場分為以下幾個部分進行分析：

按類型

  • 免疫檢測（RIA）
  • 酵素免疫分析法測定或酵素結合免疫吸附檢測法（ELISA）
  • 計數免疫檢測(CIA)
  • 螢光免疫分析(FIA)
  • 化學冷光免疫檢測(CLIA)

按治療區域

  • 感染疾病
  • 骨骼代謝
  • 免疫學
  • 神經生物學
  • 其他

按最終用戶

  • 醫院/診所
  • 診斷實驗室
  • 製藥和生物技術公司
  • 研究/學術機構

按地區

  • 北美洲
  • 美國
  • 加拿大
  • 墨西哥
  • 南美洲
  • 巴西
  • 阿根廷
  • 其他
  • 歐洲
  • 英國
  • 法國
  • 德國
  • 義大利
  • 其他
  • 中東/非洲
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 其他
  • 亞太地區
  • 日本
  • 中國
  • 印度
  • 泰國
  • 台灣
  • 印尼
  • 其他

目錄

第1章簡介

  • 市場概況
  • 市場定義
  • 調查範圍
  • 市場區隔
  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關人員的主要利益

第2章調查方法

  • 研究設計
  • 調查過程

第3章執行摘要

  • 主要發現

第4章市場動態

  • 市場促進因素
  • 市場限制因素
  • 波特五力分析
  • 產業價值鏈分析
  • 分析師觀點

第5章免疫檢測市場：依類型

  • 介紹
  • 免疫檢測（RIA）
  • 酵素免疫分析法測定或酵素結合免疫吸附檢測法（ELISA）
  • 計數免疫檢測(CIA)
  • 螢光免疫分析(FIA)
  • 化學冷光免疫檢測(CLIA)

第6章免疫檢測市場：依治療領域

  • 介紹
  • 感染疾病
  • 骨骼代謝
  • 免疫學
  • 神經生物學
  • 其他

第7章免疫檢測市場：依最終用戶分類

  • 介紹
  • 醫院/診所
  • 診斷實驗室
  • 製藥和生物技術公司
  • 研究/學術機構

第8章免疫檢測市場：按地區

  • 介紹
  • 北美洲
    • 按類型
    • 按治療區域
    • 按最終用戶
    • 按國家/地區
  • 南美洲
    • 按類型
    • 按治療區域
    • 按最終用戶
    • 按國家/地區
  • 歐洲
    • 按類型
    • 按治療區域
    • 按最終用戶
    • 按國家/地區
  • 中東/非洲
    • 按類型
    • 按治療區域
    • 按最終用戶
    • 按國家/地區
  • 亞太地區
    • 按類型
    • 按治療區域
    • 按最終用戶
    • 按國家/地區

第9章競爭環境及分析

  • 主要企業及策略分析
  • 市場佔有率分析
  • 合併、收購、協議和合作
  • 競爭對手儀表板

第10章 公司簡介

  • Fujirebio
  • QuidelOrtho Corporation
  • Roche Diagnostics
  • Immunodiagnostic Systems
  • Arbor Assays
  • Beckman Coulter Inc.
  • ImmunoReagents Inc.
  • Abbott
  • Mercodia AB
  • Thermo Fisher Scientific
  • Siemens Healthineers
  • Bio-Rad Laboratories
簡介目錄
Product Code: KSI061611644

The immunoassay market is estimated to grow at a CAGR of 6.46%, reaching US$48.644 billion by 2030 from US$35.571 billion in 2025.

Immunoassays are bioanalytical methods that employ antigen-antibody affinity to identify and quantify molecules of interest in biological samples. They are quick and accurate tests performed in the lab for the identification of particular substances.

The increase in the cases of chronic illnesses such as cancer, diabetes, cardiovascular, and autoimmune diseases is mostly responsible for the immunoassays market growth as they are important in early diagnosis and monitoring for improved disease management.

The global prevalence of diabetes for the adult (20-79 years) age group is projected to increase to 643 million by 2030, as per the estimates provided by the International Diabetes Federation (IDF). The number is projected to rise to 783 million by 2045, which was around 537 million in 2021. The statistics portray that there will be an increasing need for early diagnosis and apparent detection devices; hence, the requirement for immunoassay will grow in the future.

Additionally, the increasing prevalence and incidence of infectious diseases are fuelling the market growth. As per the World Health Organization data released in May 2024, the burden of healthcare-associated infections and antimicrobial resistance is substantial, with more than 24% of patients with sepsis, 52.3% of patients in the intensive care unit dying every year, and patients with antimicrobial-resistant infections increasing two to three times the death rates.

In addition, public health education campaigns focusing on recognizing the signs of different infectious diseases and how to take precautions against them help in the growing of public awareness and the management of other diseases. This increased patient awareness is expected to lead to high demand for immunoassays.

Immunoassay market growth drivers

  • Increasing Prevalence of Chronic Diseases

There has been an increase in the number of individuals suffering from chronic diseases such as cancer and diabetes, among others. Due to this, there has been a growth in the necessity of immunoassay devices that are used to detect a particular biomarker in a patient. The International Agency for Research on Cancer (IARC) provided statistics on absolute new cases of cancer and cancer incidence in global regions in 2022. In Asia, there was an incidence of 9.826 million cancers, which accounted for the highest number of cases, which was 49.2% of total incidences. Followed by Europe at 22.4% with 4.471 million cancer cases and Northern America at 13.4%, that is, 2.673 million cases of cancers. Immunoassays are essential in the collection of chronic illness biomarkers to improve the treatment management of patients. These assist in medicine personalization, where patients' treatment plans are designed according to their disease condition, followed by monitoring treatment response and modification of the treatment strategy after the disease diagnosis.

Immunoassay market geographical outlook:

  • The Asia Pacific region is expected to witness significant growth in the immunoassay market.

Asia Pacific is poised to hold a prominent position in the immunoassay market, particularly due to its growing investment in robust healthcare infrastructure and the increasing prevalence of chronic diseases. The Japanese immunoassay market is displaying stable growth. Its growth has been characterized by an aging population, a high prevalence of chronic diseases, and increased demand for early diagnostic tools. Japan boasts some of the world's best healthcare infrastructure and quality care, with implementations of immunoassay technologies widespread in most of its hospitals, clinics, and research institutions. The proportion of Japan's elderly population, representing a percentage of the total population, witnessed a gradual increase, reaching 28.56% in 2020, 28.86% in 2021, and 29.00% in 2022. The RUO immunoassay is an invaluable tool for research to diagnose and treat this growing chronic disease ailment in the population.

Further major developments such as Sysmex Corporation, headquartered in Kobe, Japan, and Fujirebio Holdings, Inc., headquartered in Tokyo, Japan, agreed on a business collaboration in October 2023. This agreement enhances their collaboration in various areas, including research and development, production, clinical development, and sales-marketing within the immunoassay field. Additionally, they have agreed on a supply agreement for reagents and raw materials specifically for immunoassay applications. Both companies will leverage their expertise and capabilities in immunoassay, which expedites their global growth and contributes significantly to advancing this field of diagnostics.

With the advancement of ultrasensitive technologies, the demand is increasing, particularly in the neurology infectious disease sector and oncology testing. The higher sensitivity enables, the discovery of new markers at lower levels in all fields, detection, and diagnosis. Hence, in the projected period, with the development of new and innovative product launches, the market for immunoassay is expected to propel.

Reasons for buying this report:-

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, other sub- segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape up future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decision to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data & forecasts from 2022 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, Customer Behaviour, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)

The Immunoassay Market is analyzed into the following segments:

By Type

  • Radioimmunoassay (RIA)
  • Enzyme Immunoassay or Enzyme-linked Immunosorbent Assays (ELISA)
  • Counting Immunoassay (CIA)
  • Fluoroimmunoassay (FIA)
  • Chemiluminescence Immunoassay (CLIA)

By Therapeutic Area

  • Infectious Diseases
  • Bone Metabolism
  • Immunology
  • Neurobiology
  • Others

By End-User

  • Hospitals & Clinics
  • Diagnostics
  • Pharmaceutical & Biotechnology Companies
  • Research & Academic Laboratories

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • UK
  • France
  • Germany
  • Italy
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • Thailand
  • Taiwan
  • Indonesia
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key benefits for the stakeholders

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Process

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. The Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. IMMUNOASSAY MARKET BY TYPE

  • 5.1. Introduction
  • 5.2. Radioimmunoassay (RIA)
  • 5.3. Enzyme Immunoassay or Enzyme-linked Immunosorbent Assays (ELISA)
  • 5.4. Counting Immunoassay (CIA)
  • 5.5. Fluoroimmunoassay (FIA)
  • 5.6. Chemiluminescence Immunoassay (CLIA)

6. IMMUNOASSAY MARKET BY THERAPEUTIC AREA

  • 6.1. Introduction
  • 6.2. Infectious Diseases
  • 6.3. Bone Metabolism
  • 6.4. Immunology
  • 6.5. Neurobiology
  • 6.6. Others

7. IMMUNOASSAY MARKET BY END-USER

  • 7.1. Introduction
  • 7.2. Hospitals & Clinics
  • 7.3. Diagnostics
  • 7.4. Pharmaceutical & Biotechnology Companies
  • 7.5. Research & Academic Laboratories

8. IMMUNOASSAY MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Type
    • 8.2.2. By Therapeutic Area
    • 8.2.3. By End-User
    • 8.2.4. By Country
      • 8.2.4.1. United States
      • 8.2.4.2. Canada
      • 8.2.4.3. Mexico
  • 8.3. South America
    • 8.3.1. By Type
    • 8.3.2. By Therapeutic Area
    • 8.3.3. By End-User
    • 8.3.4. By Country
      • 8.3.4.1. Brazil
      • 8.3.4.2. Argentina
      • 8.3.4.3. Others
  • 8.4. Europe
    • 8.4.1. By Type
    • 8.4.2. By Therapeutic Area
    • 8.4.3. By End-User
    • 8.4.4. By Country
      • 8.4.4.1. UK
      • 8.4.4.2. France
      • 8.4.4.3. Germany
      • 8.4.4.4. Italy
      • 8.4.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. By Type
    • 8.5.2. By Therapeutic Area
    • 8.5.3. By End-User
    • 8.5.4. By Country
      • 8.5.4.1. Saudi Arabia
      • 8.5.4.2. UAE
      • 8.5.4.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. By Type
    • 8.6.2. By Therapeutic Area
    • 8.6.3. By End-User
    • 8.6.4. By Country
      • 8.6.4.1. Japan
      • 8.6.4.2. China
      • 8.6.4.3. India
      • 8.6.4.4. Thailand
      • 8.6.4.5. Taiwan
      • 8.6.4.6. Indonesia
      • 8.6.4.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Fujirebio
  • 10.2. QuidelOrtho Corporation
  • 10.3. Roche Diagnostics
  • 10.4. Immunodiagnostic Systems
  • 10.5. Arbor Assays
  • 10.6. Beckman Coulter Inc.
  • 10.7. ImmunoReagents Inc.
  • 10.8. Abbott
  • 10.9. Mercodia AB
  • 10.10. Thermo Fisher Scientific
  • 10.11. Siemens Healthineers
  • 10.12. Bio-Rad Laboratories